Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone propionate/salmeterol - GSK

Next Previous
X
Search
Drug Profile

Fluticasone propionate/salmeterol - GSK

Alternative Names: Adoair Aerosol; Adoair Diskus; Advair Diskus; Advair HFA; Anasma Accuhaler; Atmadisc; Fluticasone propionate/salmeterol; Inaladuo; Plusvent Accuhaler; salmeterol xinafoate/fluticasone propionate; Seretide; Seretide Accuhaler; Seretide Diskus; Seretide Evohaler; Seretide MDI; Viani

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glaxo Wellcome SA; GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Discontinued Rhinitis

Most Recent Events

  • 14 Sep 2020 No development reported - Phase-III for Asthma (In adolescents, In children, In adults) in Mexico, Chile, Spain, Romania, Russia, Netherlands, South Korea, Germany, Czech Republic, Brazil, Argentina (Inhalation)
  • 20 Dec 2017 GlaxoSmithKline received label changes approval to remove the boxed warning for fluticasone propionate/ salmeterol
  • 01 Nov 2016 GlaxoSmithKline completes a phase III trial in Asthma (In Children, In adults, In adolescents) in USA, Argentina, Brazil, Chile, Czech Republic, Germany, South Korea, Mexico, Netherlands, Romania, Russia and Spain (Inhalation, Powder) (NCT02301975)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top